Bristol Myers Squibb - News
WEBStay updated on the latest news from Bristol Myers Squibb, a global biopharmaceutical company dedicated to developing and delivering innovative medicines for serious diseases.
Bristol Myers Squibb - News
WEBSep 18, 2024 — Bristol Myers Squibb Presents New Data from Two Trials Demonstrating Sotyktu (deucravacitinib) Efficacy in both Moderate-to-Severe Scalp Psoriasis and in a Real-World Setting
Bristol Myers Squibb - Bristol Myers Squibb Completes Acquisition …
WEBMar 18, 2024 — Bristol Myers Squibb will provide an update to its financial outlook when it reports first quarter 2024 results on April 25, 2024. Advisors. Gordon Dyal & Co. and Citi are serving as financial advisors to Bristol Myers Squibb, and Covington & Burling LLP is serving as legal counsel.
Bristol Myers Squibb Strengthens and Diversifies Oncology …
WEBOct 8, 2023 — Bristol Myers Squibb to Acquire Mirati for $58.00 Per Share, Representing $4.8 Billion Equity Value and Up to $5.8 Billion Including the Contingent Value Right Acquisition Brings KRAZATI® (adagrasib), a Best-in-Class KRASG12C Inhibitor Approved by the U.S. FDA for the Treatment of Patients with …
Bristol Myers Squibb - Bristol Myers Squibb Adds Premier ...
WEBDec 26, 2023 — PRINCETON, N.J. & SAN DIEGO--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) and RayzeBio, Inc. (NASDAQ: RYZB) today announced a definitive merger agreement under which Bristol Myers Squibb will acquire RayzeBio for $62.50 per share in cash, for a total equity value of approximately $4.1 billion, or $3.6 billion net of estimated cash ...
Bristol Myers Squibb - U.S. Food and Drug Administration …
WEBSep 9, 2022 — Bristol Myers Squibb’s Sotyktu, a first-in-class, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, is the only approved TYK2 inhibitor worldwide and the first innovation in oral treatment for moderate-to-severe plaque psoriasis in nearly 10 years
Bristol Myers Squibb - Bristol Myers Squibb to Acquire Turning …
WEBJun 3, 2022 — NEW YORK & SAN DIEGO--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE:BMY) and Turning Point Therapeutics, Inc. (NASDAQ:TPTX) today announced a definitive merger agreement under which Bristol Myers Squibb will acquire Turning Point Therapeutics for $76.00 per share. The transaction was unanimously approved by both the Bristol Myers Squibb and ...
Bristol Myers Squibb Announces Leadership Transition Plan
WEBApr 26, 2023 — NEW YORK--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced that Giovanni Caforio, MD, Chairman of the Board and Chief Executive Officer, has decided to retire as Chief Executive Officer, effective November 1, 2023. Christopher Boerner, PhD, EVP, Chief Commercialization Officer, has been named EVP, Chief Operating Officer ...
Bristol Myers Squibb - U.S. FDA Approves Bristol Myers Squibb’s …
WEBJun 24, 2022 — Bristol Myers Squibb: Creating a Better Future for People with Cancer. Bristol Myers Squibb is inspired by a single vision—transforming patients’ lives through science. The goal of the company’s cancer research is to deliver medicines that offer each patient a better, healthier life and to make cure a possibility.
Bristol Myers Squibb - Bristol-Myers Squibb Completes …
WEBNov 20, 2019 — Bristol-Myers Squibb Company (NYSE:BMY) announced today that it has completed its acquisition of Celgene Corporation (NASDAQ:CELG) following the receipt of regulatory approval from all government authorities required by the merger agreement and, as announced on April 12, 2019, approval by Bristol-Myers Squibb and …